- About EAS
|Highlighted articles January|
By Simona Negrini and Arnold von Eckardstein (Editor–in-Chief).
Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors
In this review, Arca M. summarizes the challenges in clinical management of subjects with heterozygous familial hypercholesterolemia (HeFH), with a focus on emerging treatments, and highlights the status of HeFH diagnosis and treatment in Italy. HeFH is a common genetic disorder associated with an elevated risk of premature coronary heart disease, stroke, and peripheral vascular disease. Despite the availability of reliable diagnostic criteria, HeFH is underdiagnosed and undertreated worldwide. HeFH is characterized by markedly elevated plasma concentrations of low-density lipoprotein cholesterol (LDL-C), but because of the high baseline levels of LDL-C, the achievement of target LDL-C levels remains a challenge. In recent years, a number of novel therapies to lower LDL-C levels in HeFH have been developed, including the monoclonal antibodies against serine protease proprotein convertase subtilisin/kexin type 9 (PCSK9), alirocumab and evolocumab, which have the potential to reduce LDL-C by an additional 50%–60% when prescribed in combination with standard lipid-lowering drugs.
Carotid artery plaques and intima medial thickness in familial hypercholesteraemic patients on long-term statin therapy: A case control study
Statins reduce subclinical atherosclerosis and premature atherosclerotic cardiovascular disease (ASCVD) in patients with familial hypercholesterolemia (FH), although some FH patients still develop ASCVD despite statin therapy. Bos et al. aimed to compare subclinical atherosclerosis in long-term statin-treated FH patients and healthy controls assessed by carotid plaque presence and intima media thickness (C-IMT).
Ideal cardiovascular health influences cardiovascular disease risk associated with high lipoprotein(a) levels and genotype: The EPIC-Norfolk prospective population study
According to the American Heart Association, “ideal cardiovascular health” can be defined on the basis of seven cardiovascular health metrics. Perrot et al. aimed to evaluate the importance of “ideal cardiovascular health” in individuals with high lipoprotein(a), which is a strong genetic risk factor for cardiovascular disease.
Low vitamin D does not predict statin associated muscle symptoms but is associated with transient increases in muscle damage and pain
Low vitamin D (VITD) may contribute to statin-associated muscle symptoms (SAMS). Taylor et al. examined the influence of baseline and change in vitamin D levels in patients with verified statin-associated muscle symptoms (SAMS).
Proprotein convertase subtilisin/kexin type 9 (PCSK9) may have extra-hepatic effects on cholesterol homeostasis of vascular macrophages. Adorni et al. investigated the role of PCSK9 in extra-hepatic cholesterol homeostasis of vascular macrophages and, in particular, its influence on the anti-atherogenic process mediated by Abca1 (ATP binding cassette transporter A1).
01/02/2017 » 01/05/2017
Abstract submission for the 40th Annual Scientific ELC meeting opens!
11/03/2017 » 14/03/2017
Immuno-Metabolic Mechanisms of Atherosclerosis